Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

The dose makes the medicine.

Stumpf WE.

Drug Discov Today. 2006 Jun;11(11-12):550-5. Review.

PMID:
16713907
2.

Hormesis [biological effects of low-level exposure (B.E.L.L.E.)] and dermatology.

Thong HY, Maibach HI.

Cutan Ocul Toxicol. 2007;26(4):329-41. Review.

PMID:
18058307
3.

Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations.

Gabrielsson J, Dolgos H, Gillberg PG, Bredberg U, Benthem B, Duker G.

Drug Discov Today. 2009 Apr;14(7-8):358-72. doi: 10.1016/j.drudis.2008.12.011. Epub 2009 Jan 20. Review.

PMID:
19162219
4.

Future of toxicology--low-dose toxicology and risk--benefit analysis.

Rietjens IM, Alink GM.

Chem Res Toxicol. 2006 Aug;19(8):977-81.

PMID:
16918235
5.

High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective.

Buckley LA, Dorato MA.

Regul Toxicol Pharmacol. 2009 Aug;54(3):301-7. doi: 10.1016/j.yrtph.2009.05.015. Epub 2009 May 27.

PMID:
19477212
6.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
7.

Positron emission tomography for use in microdosing studies.

Wagner CC, Müller M, Lappin G, Langer O.

Curr Opin Drug Discov Devel. 2008 Jan;11(1):104-10. Review.

PMID:
18175273
8.
9.
10.

Using exposure-response and biomarkers to streamline early drug development.

Venitz J.

Ernst Schering Res Found Workshop. 2007;(59):47-63. Review.

PMID:
17117714
11.

Smarter candidate selection--utilizing microdosing in exploratory clinical studies.

Buchan P.

Ernst Schering Res Found Workshop. 2007;(59):7-27. Review.

PMID:
17117712
12.

Improving early drug discovery through ADME modelling: an overview.

Wishart DS.

Drugs R D. 2007;8(6):349-62. Review.

PMID:
17963426
13.

What does systems biology mean for drug development?

Schrattenholz A, Soskić V.

Curr Med Chem. 2008;15(15):1520-8. Review.

PMID:
18537627
14.

Chemotherapeutics and hormesis.

Calabrese EJ, Baldwin LA.

Crit Rev Toxicol. 2003;33(3-4):305-53. Review.

PMID:
12809428
16.

Drug localization and targeting with receptor microscopic autoradiography.

Stumpf WE.

J Pharmacol Toxicol Methods. 2005 Jan-Feb;51(1):25-40. Review.

PMID:
15596112
17.

Effective integration of systems biology, biomarkers, biosimulation and modelling in streamlining drug development.

Krishna R, Schaefer HG, Bjerrum OJ.

Eur J Pharm Sci. 2007 May;31(1):62-7. Epub 2007 Feb 20.

PMID:
17408933
18.

Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment.

Smith DA, Obach RS.

Chem Res Toxicol. 2009 Feb;22(2):267-79. doi: 10.1021/tx800415j. Review.

PMID:
19166333
19.

Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.

EFSA GMO Panel Working Group on Animal Feeding Trials.

Food Chem Toxicol. 2008 Mar;46 Suppl 1:S2-70. doi: 10.1016/j.fct.2008.02.008. Epub 2008 Feb 13. Review.

PMID:
18328408
20.

Issues in the design and interpretation of chronic toxicity and carcinogenicity studies in rodents: approaches to dose selection.

Rhomberg LR, Baetcke K, Blancato J, Bus J, Cohen S, Conolly R, Dixit R, Doe J, Ekelman K, Fenner-Crisp P, Harvey P, Hattis D, Jacobs A, Jacobson-Kram D, Lewandowski T, Liteplo R, Pelkonen O, Rice J, Somers D, Turturro A, West W, Olin S.

Crit Rev Toxicol. 2007;37(9):729-837. Review.

PMID:
17957539

Supplemental Content

Support Center